Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
复制标题
DOI：
10.1111/liv.15405
复制
发表时间：
2022-11
影响因子：
6.7
通讯作者：
Sharma, Rohini
中科院分区：
文献类型：
--
作者：
Vithayathil, Mathew;D'Alessio, Antonio;Fulgenzi, Claudia A. M.;Nishida, Naoshi;Schoenlein, Martin;von Felden, Johann;Schulze, Kornelius;Wege, Henning;Saeed, Anwaar;Wietharn, Brooke;Hildebrand, Hannah;Wu, Linda;Ang, Celina;Marron, Thomas U.;Weinmann, Arndt;Galle, Peter R.;Bettinger, Dominik;Bengsch, Bertram;Vogel, Arndt;Balcar, Lorenz;Scheiner, Bernhard;Lee, Pei-Chang;Huang, Yi-Hsiang;Amara, Suneetha;Muzaffar, Mahvish;Naqash, Abdul Rafeh;Cammarota, Antonella;Personeni, Nicola;Pressiani, Tiziana;Pinter, Matthias;Cortellini, Alessio;Kudo, Masatoshi;Rimassa, Lorenza;Pinato, David J.;Sharma, Rohini
关键词：
联合应用阿替唑单抗/贝伐单抗是不能切除的肝细胞癌一线治疗的黄金标准。我们的研究调查了老年肝细胞癌患者联合治疗的有效性和安全性。来自8个中心的191名连续接受阿特唑单抗和贝伐单抗治疗的患者被纳入研究对象。根据RECISTV1.1定义的总生存期(OS)、无进展生存期(PF)、总有效率(ORR)和疾病控制率(DCR)分别在年龄较大(年龄 ≥ 65 )和较年轻(年龄 <； 65 )的患者中进行测量。评估治疗相关不良事件(TRAE)。老年人(n=1116)非酒精性脂肪性肝病的发生率较高(19.8%vs.2.7%；p <； .001)，肿瘤较小(6.2cmvs.7.9cmvs.7.9cmp=0.02)，门静脉血栓形成较少(31.9vs54.7%，p=0.002)，出现bclc-C期疾病的患者较少(50.9vs.74.3%，p=0.002)。两组间OS(中位数14.9个 月对15.1个 月；HR 1.15，95%CI 0.65-2.02 p=5.63)和PFS(中位数7.1个月对5.5个月；HR 1.11，95%CI 0.54~1.92；p=5.72)差异无统计学意义。与年轻患者相比，老年患者的ORR(27.6%比20.0%；p=2.27)和DCR(77.5%比66.1%；p=5.11)相似。与阿替唑单抗相关的(40.5%比48.0%；p=4.31)和与贝伐单抗相关的(44.8%比41.3%；p=4.63)TRAE在组间具有可比性。老年患者和年轻患者之间 ≥3级TRAE和毒性相关治疗的停用率相似。与年轻患者相比，75 及以上患者的生存和安全结果相似。在老年不能切除的肝细胞癌患者中，阿替唑单抗和贝伐单抗治疗的疗效和耐受性相似。
Combination atezolizumab/bevacizumab is the gold standard for first‐line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. 191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression‐free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age ≥ 65 years) and younger (age < 65 years) age patients. Treatment‐related adverse events (trAEs) were evaluated. The elderly (n = 116) had higher rates of non‐alcoholic fatty liver disease (19.8% vs. 2.7%; p < .001), presenting with smaller tumours (6.2 cm vs 7.9 cm, p = .02) with less portal vein thrombosis (31.9 vs. 54.7%, p = .002), with fewer patients presenting with BCLC‐C stage disease (50.9 vs. 74.3%, p = .002). There was no significant difference in OS (median 14.9 vs. 15.1 months; HR 1.15, 95% CI 0.65–2.02 p = .63) and PFS (median 7.1 vs. 5.5 months; HR 1.11, 95% CI 0.54–1.92; p = .72) between older age and younger age. Older patients had similar ORR (27.6% vs. 20.0%; p = .27) and DCR (77.5% vs. 66.1%; p = .11) compared to younger patients. Atezolizumab‐related (40.5% vs. 48.0%; p = .31) and bevacizumab‐related (44.8% vs. 41.3%; p = .63) trAEs were comparable between groups. Rates of grade ≥3 trAEs and toxicity‐related treatment discontinuation were similar between older and younger age patients. Patients 75 years and older had similar survival and safety outcomes compared to younger patients. Atezolizumab and bevacizumab therapy is associated with comparable efficacy and tolerability in older age patients with unresectable HCC.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
8.8
作者：
Hajiev S;Allara E;Motedayеn Aval L;Arizumi T;Bettinger D;Pirisi M;Rimassa L;Pressiani T;Personeni N;Giordano L;Kudo M;Thimme R;Park JW;Taddei TH;Kaplan DE;Ramaswami R;Pinato DJ;Sharma R
通讯作者：
Sharma R
DOI：
10.1111/j.1440-1746.2009.06037.x
发表时间：
2010-02-01
影响因子：
4.1
作者：
Hiraoka, Atsushi;Michitaka, Kojiro;Onji, Morikazu
通讯作者：
Onji, Morikazu
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
25.7
作者：
Cheng, Ann-Lii;Qin, Shukui;Finn, Richard S.
通讯作者：
Finn, Richard S.